NACDS’ Steve Anderson co-authors op-ed on pharmacist provider status
BOSTON — With the National Association of Chain Drug Stores Total Store Expo currently underway in Boston, the Boston Globe published an op-ed in its opinion section, Podium, which was co-authored by Steven Anderson, president and CEO of NACDS and Michael Malloy, PharmD and dean of the MCPHS University School of Pharmacy – Worcester/Manchester.
The piece focuses on proposed legislation that would allow pharmacists to help patients in underserved communities receive quality are, also while helping to reduce healthcare costs. Excerpts from the op-ed are below, and the full text can be viewed here:
“Proposed bipartisan legislation in the US House of Representatives — H.R. 4190 — would increase accessibility to affordable health care services for Medicare beneficiaries who are in medically underserved communities. The law would allow pharmacists under Medicare Part B to provide medically underserved communities with services that pharmacists are currently permitted to administer according to state law.
“This would not only begin to improve the health of people in medically underserved communities, it would help reduce the health care costs that burden our communities, businesses, and government by better managing chronic health issues that, if not managed closely, can lead to repeated hospital admissions or catastrophic situations.
“There are currently more than 4,000 licensed pharmacists in Massachusetts working in neighborhood pharmacies across the Commonwealth. The enactment of H.R. 4190 would allow these qualified health care professionals to get to work for medically underserved communities in Massachusetts and perform for Medicare patients important services such as vaccination screening and delivery, chronic disease management, medication therapy management, and preventive screenings such as testing of glucose, blood pressure, and cholesterol levels.
“A July Internet survey of likely voters who are informed and engaged when it comes to current events found that 79 percent of respondents favor the legislation — including 36 percent who strongly favor it. The survey, conducted by Public Opinion Strategies and commissioned by the National Association of Chain Drug Stores, also found tremendous bipartisan support, with 85 percent of Democrats and 76 percent of Republicans supporting it. This reflects the bill’s current co-sponsorship, with 50 Democrats and 44 Republicans cosponsoring it in the US House of Representatives.”
Mallinckrodt adds to executive leadership team
DUBLIN — Mallinckrodt last week announced that Gary Phillips, MD, currently the company's senior vice president and chief strategy office, has been named senior vice president and president of the company's autoimmune and rare disease business. The company also announced that Ray Furey, previously a senior vice president and chief compliance officer at Questcor Pharmaceuticals, was named senior vice president and the chief compliance officer at Mallinckrodt.
Phillips will take responsibility for the Acthar franchise and all of its sales, support and service initiatives. Furey's relationship will include reporting to the Mallinckrodt board of directors. Both will serve on the company's executive committee and will report directly to Mark Trudeau, the company's CEO.
“I look forward to working closely with Gary and Ray as we create a diversified, high-growth specialty pharmaceuticals company, with significantly increased scale, revenues, profitability and cash flow,” said Mark Trudeau, president and CEO of Mallinckrodt. “Since joining Mallinckrodt last year, Gary has brought focus to our growth strategy and energized our BD&L activities. Gary was one of the key architects of the Questcor transaction, and we are confident that he will achieve strong revenue and profit growth as we successfully expand the business into new indications. Ray is joining our team after more than two decades in the pharmaceutical industry. He has tremendous expertise and direct experience in compliance at leading global pharmaceutical companies. We are looking forward to having him as part of the Executive Committee and to the strong contributions he will provide to our expanded business.”
A search is underway for the chief strategy officer position, the company stated.
Walgreens’ Gleeson receives IMS’ Bernie Greenberg Award
BOSTON — IMS Health VP global supply services Hossam Sadek (right) presented the IMS Health Bernie Greenberg Pharmacy Partnership Award to Walgreens group VP pharmaceutical development, Gerry Gleeson, during an Insight Session Sunday morning. The award is named for longtime industry veteran Bernard “Bernie” Greenberg, who spent 35 years with Bristol Myers — including leading the company’s generic unit, Apothecon — before beginning a second career as a consultant for IMS Health and Novo Nordisk.